Cytokinetics announced strikingly positive Phase 3 results for Myqorzo (aficamten) in non‑obstructive hypertrophic cardiomyopathy (nHCM) on May 5. The ACACIA‑HCM trial cleared both primary endpoints, improvement in the Kansas City Cardiomyopathy Questionnaire and in maximal exercise capacity versus placebo at Week 36. Each measure showed statistically solid gains, consistent across subgroups. Myqorzo, already FDA‑approved since December 2025 for obstructive HCM, now positions Cytokinetics to seek the first approval ever in nHCM. Shares jumped more than 20% Monday morning as CEO Robert Blum and R&D chief Fady Malik described the data as “transformational.” The company expects to engage the FDA quickly on next steps, signaling confidence rather than caution.
This moment looks less like incremental progress and more like a turning point for Cytokinetics and the entire myosin‑inhibitor class. Myqorzo’s success extends that mechanism into a population that has never before seen a positive trial, effectively doubling its potential reach based on the company’s internal claims analysis. Should regulators agree with the evidence package, Cytokinetics could transform Myqorzo into a chronic therapy franchise touching both obstructive and non‑obstructive disease, territory long considered scientifically out of reach. That kind of move forces rivals, notably Bristol Myers Squibb’s Camzyos program, to rethink whether they’ve underestimated nHCM’s commercial pull.
Investors and payers now face a reshaped landscape. Cytokinetics holds a unique position to set pricing logic and access rules in this newly defined segment. A label expansion would also test payer tactics around step‑therapy decisions across the two cardiomyopathy codes. Beyond that, the strength of these data and the company’s clean positioning as first mover could restart serious M&A conversations. Nobody really knows how fast uptake might run, but the signal is no longer niche, it’s an early outline of a multi‑segment cardiomyopathy market. And frankly, it feels overdue. Detailed drug monographs are available at ClinicalRx.ai.
